Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: August 24, 2009
Last updated: November 26, 2013
Last verified: November 2013

This trial is conducted in Europe. The aim is to compare changes in blood sugar and the number of periods where carbohydrate supplementation is needed to treat low blood sugar, during two different treatments with NN1250 (insulin degludec), a soluble insulin basal analogue (SIBA) in subjects with type 1 diabetes.

Condition Intervention Phase
Diabetes Mellitus, Type 1
Drug: insulin degludec
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Trial Assessing the Number of Hypoglycaemic Episodes and Glycaemic Variability During Two Different Regimens of SIBA 200 U/ml in Subjects With Type 1 Diabetes

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Total number of periods where carbohydrate supplementation is needed during the treatment [ Time Frame: Assessed every day of the two in-house stays of nine days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Frequency of adverse events (AEs) [ Time Frame: Assessed every day of the two in-house stays of nine days and one follow-up by telephone ] [ Designated as safety issue: No ]
  • Number of periods with low blood sugar during treatment [ Time Frame: Assessed every day of the two in-house stays of nine days and one follow-up by telephone ] [ Designated as safety issue: Yes ]

Enrollment: 18
Study Start Date: August 2009
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SIBA 3W Drug: insulin degludec
Insulin degludec injected s.c. (under the skin) three times weekly
Drug: placebo
Placebo injected s.c. (under the skin) four times weekly
Experimental: SIBA OD Drug: insulin degludec
Insulin degludec injected s.c. (under the skin) once daily for one week


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 diabetes mellitus for at least 12 months
  • Glycosylated haemoglobin (HbA1c) between 7.5 and 9% (both inclusive)

Exclusion Criteria:

  • Donation or loss of more than 500 ml blood or plasma within three months prior to this trial
  • Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) or not able or willing to refrain from smoking and the use of nicotine gum or transdermal nicotine patches during the in-house periods
  • Prior or current treatment with metformin or thiazolidinediones
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00964964

Neuss, Germany, 41460
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
No publications provided

Responsible Party: Novo Nordisk A/S Identifier: NCT00964964     History of Changes
Other Study ID Numbers: NN1250-3765, 2009-011959-53
Study First Received: August 24, 2009
Last Updated: November 26, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Insulin, Globin Zinc
Insulin, Long-Acting
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 25, 2014